Ranbaxy shares fall on USFDA concerns

Ranbaxy Laboratories shares fall 1.3 percent, adding to Monday's 5.4 percent slump after the

RELATED ARTICLES

U.S. Food and Drug Administration raised concerns about manufacturing practices at one of its factories.

Macquarie and Jefferies downgrade Ranbaxy, saying the FDA uncertainty could put pressure on valuations in the near-term till further clarity emerges.

Macquarie downgrades the stock to "neutral" from "outperform" and cuts the price target to 450 rupees from 500 rupees, while Jefferies cuts Ranbaxy to "underperform" from "hold" with a price target of 350 rupees.

Ranbaxy said on Monday the FDA has filed "certain observations" about its Toansa pharmaceutical ingredients plant in the northern Indian state of Punjab.

"The issue also increases the risk of delay in resolution of import alerts and launch of products," Jefferies said in a note to clients.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Salman should be punished for what he did and not for who he is

    Salman Khan is a Bollywood phenomenon. On the professional front, he can do no wrong.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Simon J Evenett

Trade policy: more heat than light?

After several years in the doldrums, trade policy is back. ...

Zehra Naqvi

Happy people are better workers

We know that the state of mind we are in ...

Dharmendra Khandal

Tales from the dry, deciduous forest of Kuno

Kuno is an incredibly dry deciduous (dhonk) tree forest of ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture